Switch to:
Also traded in: Denmark, Germany, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
GNMSF's Cash-to-Debt is ranked higher than
87% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. GNMSF: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GNMSF' s Cash-to-Debt Range Over the Past 10 Years
Min: 10.54  Med: 4728.54 Max: 59161.39
Current: No Debt
10.54
59161.39
Equity-to-Asset 0.90
GNMSF's Equity-to-Asset is ranked higher than
85% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. GNMSF: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
GNMSF' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.21  Med: 0.52 Max: 0.91
Current: 0.9
0.21
0.91
Interest Coverage 23.80
GNMSF's Interest Coverage is ranked lower than
80% of the 463 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNMSF: 23.80 )
Ranked among companies with meaningful Interest Coverage only.
GNMSF' s Interest Coverage Range Over the Past 10 Years
Min: 17.98  Med: 6189.65 Max: No Debt
Current: 23.8
Piotroski F-Score: 6
Altman Z-Score: 121.78
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 49.22
GNMSF's Operating Margin % is ranked higher than
96% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. GNMSF: 49.22 )
Ranked among companies with meaningful Operating Margin % only.
GNMSF' s Operating Margin % Range Over the Past 10 Years
Min: -348.38  Med: -49.34 Max: 64.46
Current: 49.22
-348.38
64.46
Net Margin % 50.24
GNMSF's Net Margin % is ranked higher than
96% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. GNMSF: 50.24 )
Ranked among companies with meaningful Net Margin % only.
GNMSF' s Net Margin % Range Over the Past 10 Years
Min: -323.31  Med: -86.46 Max: 67.39
Current: 50.24
-323.31
67.39
ROE % 20.73
GNMSF's ROE % is ranked higher than
92% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. GNMSF: 20.73 )
Ranked among companies with meaningful ROE % only.
GNMSF' s ROE % Range Over the Past 10 Years
Min: -112.03  Med: -29.6 Max: 27.67
Current: 20.73
-112.03
27.67
ROA % 18.57
GNMSF's ROA % is ranked higher than
96% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. GNMSF: 18.57 )
Ranked among companies with meaningful ROA % only.
GNMSF' s ROA % Range Over the Past 10 Years
Min: -36.89  Med: -20.21 Max: 22.56
Current: 18.57
-36.89
22.56
ROC (Joel Greenblatt) % 2555.66
GNMSF's ROC (Joel Greenblatt) % is ranked higher than
99% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. GNMSF: 2555.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GNMSF' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -675.71  Med: -31.43 Max: 2780.55
Current: 2555.66
-675.71
2780.55
3-Year Revenue Growth Rate 21.00
GNMSF's 3-Year Revenue Growth Rate is ranked higher than
72% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. GNMSF: 21.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
GNMSF' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 4.5 Max: 326.8
Current: 21
0
326.8
» GNMSF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GNMSF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology  
Compare:NAS:GRFS, OTCPK:NVZMY, NAS:MDVN, OTCPK:UCBJF, NAS:SGEN, NAS:ALKS, NAS:BMRN, NAS:TSRO, NAS:JAZZ, NAS:UTHR, NAS:EXEL, NAS:BIVV, NAS:IONS, NAS:ARIA, NAS:ALNY, NAS:KITE, NAS:ACAD, NAS:TECH, NAS:GLPG, NAS:BLUE » details
Traded in other countries:GEN.Denmark, GE9.Germany, 0MGB.UK,
Genmab A/S is an antibody company focused on cancer. Its first marketed product is Arzerra (ofatumumab); development pipeline incl. daratumumab and two proprietary technology platforms; DuoBody (bispecifics) & HexaBody (effector function enhancement).

Genmab A/S is an international biotechnology company that creates and develops differentiated antibody therapeutics focused on the treatment of cancer. The company also has a broad clinical and preclinical product pipeline. Genmab's technology base consists of validated and proprietary next-generation antibody technologies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab utilizes strategic partnerships with pharmaceutical and biotechnology companies to help fund its research and development activities and bring products to the market.

Ratios

vs
industry
vs
history
PE Ratio 116.78
GNMSF's PE Ratio is ranked lower than
89% of the 272 Companies
in the Global Biotechnology industry.

( Industry Median: 27.67 vs. GNMSF: 116.78 )
Ranked among companies with meaningful PE Ratio only.
GNMSF' s PE Ratio Range Over the Past 10 Years
Min: 42.72  Med: 88.38 Max: 133.3
Current: 116.78
42.72
133.3
PE Ratio without NRI 116.78
GNMSF's PE Ratio without NRI is ranked lower than
89% of the 261 Companies
in the Global Biotechnology industry.

( Industry Median: 28.79 vs. GNMSF: 116.78 )
Ranked among companies with meaningful PE Ratio without NRI only.
GNMSF' s PE Ratio without NRI Range Over the Past 10 Years
Min: 42.64  Med: 88.16 Max: 181.04
Current: 116.78
42.64
181.04
Price-to-Owner-Earnings 175.31
GNMSF's Price-to-Owner-Earnings is ranked lower than
91% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 26.25 vs. GNMSF: 175.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GNMSF' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 124.69  Med: 290.87 Max: 712.66
Current: 175.31
124.69
712.66
PB Ratio 21.50
GNMSF's PB Ratio is ranked lower than
94% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. GNMSF: 21.50 )
Ranked among companies with meaningful PB Ratio only.
GNMSF' s PB Ratio Range Over the Past 10 Years
Min: 1.63  Med: 9.59 Max: 25.04
Current: 21.5
1.63
25.04
PS Ratio 58.86
GNMSF's PS Ratio is ranked lower than
77% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. GNMSF: 58.86 )
Ranked among companies with meaningful PS Ratio only.
GNMSF' s PS Ratio Range Over the Past 10 Years
Min: 3.08  Med: 15.42 Max: 68.87
Current: 58.86
3.08
68.87
Price-to-Free-Cash-Flow 136.33
GNMSF's Price-to-Free-Cash-Flow is ranked lower than
93% of the 137 Companies
in the Global Biotechnology industry.

( Industry Median: 22.69 vs. GNMSF: 136.33 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GNMSF' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.77  Med: 110.44 Max: 4518.94
Current: 136.33
3.77
4518.94
Price-to-Operating-Cash-Flow 131.30
GNMSF's Price-to-Operating-Cash-Flow is ranked lower than
90% of the 193 Companies
in the Global Biotechnology industry.

( Industry Median: 23.59 vs. GNMSF: 131.30 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GNMSF' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.67  Med: 116.74 Max: 1512.17
Current: 131.3
3.67
1512.17
EV-to-EBIT 107.85
GNMSF's EV-to-EBIT is ranked lower than
94% of the 250 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. GNMSF: 107.85 )
Ranked among companies with meaningful EV-to-EBIT only.
GNMSF' s EV-to-EBIT Range Over the Past 10 Years
Min: -390.3  Med: 12.2 Max: 1482
Current: 107.85
-390.3
1482
EV-to-EBITDA 107.85
GNMSF's EV-to-EBITDA is ranked lower than
92% of the 274 Companies
in the Global Biotechnology industry.

( Industry Median: 15.67 vs. GNMSF: 107.85 )
Ranked among companies with meaningful EV-to-EBITDA only.
GNMSF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1007.1  Med: 9.2 Max: 1482
Current: 107.85
-1007.1
1482
Current Ratio 9.89
GNMSF's Current Ratio is ranked higher than
80% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. GNMSF: 9.89 )
Ranked among companies with meaningful Current Ratio only.
GNMSF' s Current Ratio Range Over the Past 10 Years
Min: 1.3  Med: 2.14 Max: 10.33
Current: 9.89
1.3
10.33
Quick Ratio 9.89
GNMSF's Quick Ratio is ranked higher than
80% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. GNMSF: 9.89 )
Ranked among companies with meaningful Quick Ratio only.
GNMSF' s Quick Ratio Range Over the Past 10 Years
Min: 1.3  Med: 2.14 Max: 10.33
Current: 9.89
1.3
10.33

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.80
GNMSF's 3-Year Average Share Buyback Ratio is ranked higher than
68% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. GNMSF: -5.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GNMSF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -19.9  Med: -5.8 Max: -0.2
Current: -5.8
-19.9
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 24.00
GNMSF's Price-to-Net-Cash is ranked lower than
86% of the 652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.34 vs. GNMSF: 24.00 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GNMSF' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 7.38  Med: 13.99 Max: 75.2
Current: 24
7.38
75.2
Price-to-Net-Current-Asset-Value 22.72
GNMSF's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 5.91 vs. GNMSF: 22.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GNMSF' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.72  Med: 8.92 Max: 24.04
Current: 22.72
1.72
24.04
Price-to-Tangible-Book 22.46
GNMSF's Price-to-Tangible-Book is ranked lower than
92% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. GNMSF: 22.46 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GNMSF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.62  Med: 8.25 Max: 22.66
Current: 22.46
1.62
22.66
Price-to-Intrinsic-Value-Projected-FCF 28.38
GNMSF's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
88% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.22 vs. GNMSF: 28.38 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
GNMSF' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 17.52  Med: 32.12 Max: 440.6
Current: 28.38
17.52
440.6
Price-to-Median-PS-Value 3.82
GNMSF's Price-to-Median-PS-Value is ranked lower than
90% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. GNMSF: 3.82 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GNMSF' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 0.99 Max: 3.82
Current: 3.82
0.24
3.82
Price-to-Graham-Number 10.80
GNMSF's Price-to-Graham-Number is ranked lower than
92% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.54 vs. GNMSF: 10.80 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GNMSF' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 4.02  Med: 6.72 Max: 10.8
Current: 10.8
4.02
10.8
Earnings Yield (Greenblatt) % 0.93
GNMSF's Earnings Yield (Greenblatt) % is ranked higher than
79% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. GNMSF: 0.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GNMSF' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 1.2 Max: 374.9
Current: 0.93
0.1
374.9

More Statistics

Revenue (TTM) (Mil) $217.6
EPS (TTM) $ 1.78
Beta0.28
Short Percentage of Float0.00%
52-Week Range $123.00 - 207.50
Shares Outstanding (Mil)60.15
» More Articles for GNMSF

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Genmab A/S :GNMSF-US: Earnings Analysis: Q4, 2016 By the Numbers : February 28, 2017 Feb 28 2017
CHMP Issues Positive Opinion Recommending DARZALEX® (daratumumab) for Relapsed or Refractory... Feb 24 2017
Genmab 2016 Annual Report Feb 22 2017
Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer Feb 08 2017
Genmab Announces Updated 2016 Financial Guidance Feb 06 2017
Genmab Announces 2016 Net Sales Figures for DARZALEX® (Daratumumab) Jan 24 2017
Genmab Achieves USD 25 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with... Jan 06 2017
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : January 6, 2017 Jan 06 2017
Why Genmab (GNMSF) Might Be a Diamond in the Rough Dec 16 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : December 6, 2016 Dec 06 2016
Genmab A/S (GNMSF): Strong Industry, Solid Earnings Estimate Revisions Dec 01 2016
Why Genmab (GNMSF) Could Shock the Market Soon Nov 28 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q3, 2016 By the Numbers : November 14, 2016 Nov 14 2016
Genmab A/S breached its 50 day moving average in a Bullish Manner : GNMSF-US : October 20, 2016 Oct 20 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : August 31, 2016 Aug 31 2016
Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More Aug 08 2016
Genmab A/S breached its 50 day moving average in a Bearish Manner : GNMSF-US : July 25, 2016 Jul 25 2016
Genmab/Novartis' Arzerra Gets Unfavorable CHMP Opinion Jun 24 2016
Market Rout Hits Genmab While Buy Ratings Signal 20% Rebound Jun 13 2016
Genmab A/S :GNMSF-US: Earnings Analysis: Q1, 2016 By the Numbers May 17 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)